BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 26002186)

  • 1. Morphometric and neurochemical alterations found in l-BMAA treated rats.
    de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Martínez A; Arahuetes RM
    Environ Toxicol Pharmacol; 2015 May; 39(3):1232-45. PubMed ID: 26002186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.
    de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of cyanobacterial neurotoxin β-N-methylamino-l-alanine within shellfish in the diet of an ALS patient in Florida.
    Banack SA; Metcalf JS; Bradley WG; Cox PA
    Toxicon; 2014 Nov; 90():167-73. PubMed ID: 25123936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editor's Highlight: Embryonic Exposure to the Environmental Neurotoxin BMAA Negatively Impacts Early Neuronal Development and Progression of Neurodegeneration in the Sod1-G93R Zebrafish Model of Amyotrophic Lateral Sclerosis.
    Powers S; Kwok S; Lovejoy E; Lavin T; Sher RB
    Toxicol Sci; 2017 May; 157(1):129-140. PubMed ID: 28123103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases.
    Bradley WG; Mash DC
    Amyotroph Lateral Scler; 2009; 10 Suppl 2():7-20. PubMed ID: 19929726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible therapy for ALS based on the cyanobacteria/BMAA hypothesis.
    Bradley WG
    Amyotroph Lateral Scler; 2009; 10 Suppl 2():118-23. PubMed ID: 19929743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three phases of research on beta-N-methylamino-L-alanine (BMAA)--a neurotoxic amino acid.
    Nunn PB
    Amyotroph Lateral Scler; 2009; 10 Suppl 2():26-33. PubMed ID: 19929728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of BMAA neurotoxicity: a critical review.
    Karamyan VT; Speth RC
    Life Sci; 2008 Jan; 82(5-6):233-46. PubMed ID: 18191417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking β-methylamino-L-alanine exposure to sporadic amyotrophic lateral sclerosis in Annapolis, MD.
    Field NC; Metcalf JS; Caller TA; Banack SA; Cox PA; Stommel EW
    Toxicon; 2013 Aug; 70():179-83. PubMed ID: 23660330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMAA--an unusual cyanobacterial neurotoxin.
    Vyas KJ; Weiss JH
    Amyotroph Lateral Scler; 2009; 10 Suppl 2():50-5. PubMed ID: 19929732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.
    Chernoff N; Hill DJ; Diggs DL; Faison BD; Francis BM; Lang JR; Larue MM; Le TT; Loftin KA; Lugo JN; Schmid JE; Winnik WM
    J Toxicol Environ Health B Crit Rev; 2017; 20(4):1-47. PubMed ID: 28598725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. beta-N-methylamino-l-alanine induces oxidative stress and glutamate release through action on system Xc(-).
    Liu X; Rush T; Zapata J; Lobner D
    Exp Neurol; 2009 Jun; 217(2):429-33. PubMed ID: 19374900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for naturally occurring cyanobacterial toxins in neurodegeneration? The beta-N-methylamino-L-alanine (BMAA) paradigm.
    Papapetropoulos S
    Neurochem Int; 2007 Jun; 50(7-8):998-1003. PubMed ID: 17296249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blue-green algae or cyanobacteria in the intestinal micro-flora may produce neurotoxins such as Beta-N-Methylamino-L-Alanine (BMAA) which may be related to development of amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson-Dementia-Complex in humans and Equine Motor Neuron Disease in horses.
    Brenner SR
    Med Hypotheses; 2013 Jan; 80(1):103. PubMed ID: 23146671
    [No Abstract]   [Full Text] [Related]  

  • 15. BMAA and Neurodegenerative Illness.
    Cox PA; Kostrzewa RM; Guillemin GJ
    Neurotox Res; 2018 Jan; 33(1):178-183. PubMed ID: 28540663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Long-term, Low-dose β-N-methylamino-L-alanine (BMAA) Exposures in Adult SOD
    Weeks RD; Banack SA; Howell S; Thunga P; Metcalf JS; Green AJ; Cox PA; Planchart A
    Neurotox Res; 2023 Oct; 41(5):481-495. PubMed ID: 37552461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolization of cyanobacteria as a risk factor for amyotrophic lateral sclerosis.
    Stommel EW; Field NC; Caller TA
    Med Hypotheses; 2013 Feb; 80(2):142-5. PubMed ID: 23246360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cyanobacterial amino acid β-N-methylamino-l-alanine perturbs the intermediary metabolism in neonatal rats.
    Engskog MK; Karlsson O; Haglöf J; Elmsjö A; Brittebo E; Arvidsson T; Pettersson C
    Toxicology; 2013 Oct; 312():6-11. PubMed ID: 23886855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord.
    Yin HZ; Yu S; Hsu CI; Liu J; Acab A; Wu R; Tao A; Chiang BJ; Weiss JH
    Exp Neurol; 2014 Nov; 261():1-9. PubMed ID: 24918341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spatial clustering of amyotrophic lateral sclerosis and the potential role of BMAA.
    Caller TA; Field NC; Chipman JW; Shi X; Harris BT; Stommel EW
    Amyotroph Lateral Scler; 2012 Jan; 13(1):25-32. PubMed ID: 22214351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.